Globus Medical/$GMED
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Globus Medical
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Ticker
$GMED
Sector
Primary listing
NYSE
Employees
5,300
Headquarters
Website
Globus Medical Metrics
BasicAdvanced
$8.2B
23.47
$2.57
1.20
-
Price and volume
Market cap
$8.2B
Beta
1.2
52-week high
$94.93
52-week low
$51.79
Average daily volume
1.3M
Financial strength
Current ratio
4.074
Quick ratio
2.095
Long term debt to equity
2.516
Total debt to equity
2.826
Profitability
EBITDA (TTM)
735.485
Gross margin (TTM)
67.10%
Net profit margin (TTM)
13.58%
Operating margin (TTM)
17.66%
Effective tax rate (TTM)
4.52%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
5.82%
Return on equity (TTM)
8.62%
Valuation
Price to earnings (TTM)
23.469
Price to revenue (TTM)
3.129
Price to book
1.9
Price to tangible book (TTM)
3.95
Price to free cash flow (TTM)
15.73
Free cash flow yield (TTM)
6.36%
Free cash flow per share (TTM)
3.839
Growth
Revenue change (TTM)
17.43%
Earnings per share change (TTM)
745.36%
3-year revenue growth (CAGR)
39.19%
10-year revenue growth (CAGR)
18.07%
3-year earnings per share growth (CAGR)
19.70%
10-year earnings per share growth (CAGR)
9.59%
What the Analysts think about Globus Medical
Analyst ratings (Buy, Hold, Sell) for Globus Medical stock.
Bulls say / Bears say
Globus Medical returned to a debt-free position in Q1 2025, after paying off $450 million in debt from the NuVasive merger, strengthening its balance sheet and reducing leverage risk. (Nasdaq)
Q1 2025 non-GAAP free cash flow set a record at $141.2 million, up 493% from the previous year, demonstrating strong cash generation. (Nasdaq)
The company completed its $250 million acquisition of Nevro Corp. in April 2025, tapping into a $2.5 billion neuromodulation market and expecting the deal to boost earnings by the second year. (RTTNews)
Globus Medical's global net sales fell 1.4% year-over-year to $598.1 million in Q1 2025, mainly due to a 7.7% drop in international revenue. (Nasdaq)
Revenue in the Enabling Technologies segment dropped 30.6% to $22.2 million in Q1 2025, indicating difficulties in deal closures within a key growth segment. (Investing.com)
Globus Medical lowered its full-year 2025 non-GAAP EPS forecast to $3.00–3.30 from $3.10–3.40, reflecting margin pressure and operational challenges. (MassDevice)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Globus Medical Financial Performance
Revenues and expenses
Globus Medical Earnings Performance
Company profitability
Globus Medical News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Globus Medical stock?
Globus Medical (GMED) has a market cap of $8.2B as of November 04, 2025.
What is the P/E ratio for Globus Medical stock?
The price to earnings (P/E) ratio for Globus Medical (GMED) stock is 23.47 as of November 04, 2025.
Does Globus Medical stock pay dividends?
No, Globus Medical (GMED) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Globus Medical dividend payment date?
Globus Medical (GMED) stock does not pay dividends to its shareholders.
What is the beta indicator for Globus Medical?
Globus Medical (GMED) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.